irinotecan has been researched along with ticlopidine in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 10 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dansette, PM; Fontana, E; Poli, SM | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Shi, D; Song, X; Yan, B; Yang, D; Yang, J | 1 |
| Saito, Y; Sawada, J | 1 |
| Bai, JP | 1 |
| Feng, X; Gui, H; Hu, G; Li, Y; Luan, X; Mao, Z; Peng, Y; Shen, J; Yan, B; Yang, J | 1 |
| Begg, EJ; Helsby, NA; Jensen, BP | 1 |
| Chowbay, B; Sutiman, N | 1 |
| Merali, Z; Paré, G; Ross, S | 1 |
| Guo, QL; Hu, G; Huang, XF; Liu, W; Ning, R; Qi, Q; Wang, XP; Yang, J; Zhan, YR | 1 |
| Guan, Y; Hafiz, MZ; He, S; Li, X; Liu, W; Wu, L; Xiong, J; Yan, B; Yang, J | 1 |
6 review(s) available for irinotecan and ticlopidine
| Article | Year |
|---|---|
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Pharmacogenomics].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Camptothecin; Cetuximab; Clopidogrel; Humans; Irinotecan; Pharmacogenetics; Tegafur; Ticlopidine | 2009 |
Ongoing challenges in drug interaction safety: from exposure to pharmacogenomics.
Topics: Administration, Oral; Camptothecin; Clopidogrel; Drug Evaluation; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inactivation, Metabolic; Injections, Intravenous; Irinotecan; Maximum Tolerated Dose; Membrane Transport Proteins; Models, Biological; Models, Statistical; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic; Ticlopidine | 2010 |
Pharmacogenetics of drug-metabolizing enzymes: the prodrug hypothesis.
Topics: Aryl Hydrocarbon Hydroxylases; Azathioprine; Camptothecin; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Enzymes; Glucuronosyltransferase; Humans; Inactivation, Metabolic; Irinotecan; Methyltransferases; Mixed Function Oxygenases; Prodrugs; Tamoxifen; Ticlopidine; Vitamin K Epoxide Reductases; Warfarin | 2012 |
The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Aspirin; Benzimidazoles; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Central Nervous System Stimulants; Clopidogrel; Dabigatran; Factor Xa Inhibitors; Genotype; Humans; Imidazolidines; Irinotecan; Isoenzymes; Methylphenidate; Oseltamivir; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Pyridines; Ticlopidine | 2014 |
8 other study(ies) available for irinotecan and ticlopidine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Interleukin-6 alters the cellular responsiveness to clopidogrel, irinotecan, and oseltamivir by suppressing the expression of carboxylesterases HCE1 and HCE2.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antiviral Agents; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Carcinoma, Hepatocellular; Cell Line, Tumor; Cells, Cultured; Clopidogrel; Dose-Response Relationship, Drug; Female; Hepatocytes; Humans; Interleukin-6; Irinotecan; Liver Neoplasms; Male; Middle Aged; Oseltamivir; Platelet Aggregation Inhibitors; RNA, Messenger; Ticlopidine | 2007 |
Lipopolysaccharide down-regulates carbolesterases 1 and 2 and reduces hydrolysis activity in vitro and in vivo via p38MAPK-NF-κB pathway.
Topics: Animals; Blotting, Western; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Cell Survival; Cells, Cultured; Clopidogrel; Down-Regulation; Enzyme Inhibitors; Genes, Reporter; Humans; Hydrolysis; Irinotecan; Lipopolysaccharides; Male; Mice; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Platelet Aggregation Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Subcellular Fractions; Ticlopidine; Transfection | 2011 |
Pharmacogenetics and its relevance to clinical practice.
Topics: Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Asian People; Camptothecin; Carbamazepine; Clopidogrel; Cytochrome P-450 CYP2C19; Glucuronosyltransferase; HLA-A Antigens; HLA-B Antigens; Humans; Irinotecan; Platelet Aggregation Inhibitors; Stevens-Johnson Syndrome; Ticlopidine; Topoisomerase I Inhibitors | 2013 |
Gambogic acid potentiates clopidogrel-induced apoptosis and attenuates irinotecan-induced apoptosis through down-regulating human carboxylesterase 1 and -2.
Topics: Antineoplastic Agents; Apoptosis; Biotransformation; Camptothecin; Carboxylesterase; Clopidogrel; Down-Regulation; Irinotecan; Ticlopidine; Xanthones | 2016 |
17β-estradiol suppresses carboxylesterases by activating c-Jun/AP-1 pathway in primary human and mouse hepatocytes.
Topics: Animals; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Clopidogrel; Enzyme Inhibitors; Estradiol; Female; Gene Expression Regulation, Enzymologic; Hepatocytes; Humans; Hydrolysis; Irinotecan; JNK Mitogen-Activated Protein Kinases; Mice; Mice, Inbred ICR; Receptors, Estrogen; Ticlopidine; Transcription Factor AP-1; Transcription, Genetic | 2018 |